PMV Pharmaceuticals, Inc. engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.
